ArticleClinical epigenetics2026
DNA methylation signatures of inflammation in youth living with perinatally-acquired HIV.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundEpigenetic modifications may illuminate mechanisms by which HIV and antiretroviral therapy (ART) exposure during critical developmental periods affect biological pathways and chronic comorbidity risk. We examined genome-wide DNA methylation (DNAm) in youth with perinatally-acquired HIV (YPHIV) compared to perinatally HIV-exposed uninfected youth (YPHEU) at two timepoints. In YPHIV, we assessed associations of HIV RNA viral load, CD4 count, and inflammation with DNAm alterations.
methodsGenome-wide DNAm was measured in peripheral blood mononuclear cells from 32 YPHIV and 7 YPHEU at two timepoints separated by at least 3 years via the PHACS Adolescent Master Protocol. Differentially methylated CpG sites were evaluated genome-wide (FDR p < 0.05 and ≥ 5% methylation difference) and across 15 pre-selected targeted genes at each timepoint. Regional and pathway enrichment analyses were conducted. Among YPHIV, genome-wide associations of HIV viral load, CD4 count, and inflammation markers with DNAm were assessed.
resultsNo genome-wide differentially methylated CpG sites were identified between YPHIV and YPHEU at either timepoint. For targeted genes, CpG sites on PSMB9 were differentially methylated at both timepoints. Among YPHIV, neither viral load nor CD4 count was associated with DNAm. In contrast, C-reactive protein was associated with 17 and 18 CpG sites at timepoints 1 and 2, respectively, with 7 overlapping genes, including two involved in blood pressure regulation and kidney function. Interleukin-6 was associated with 3 and 2 CpG sites at timepoints 1 and 2, respectively, with 2 overlapping genes involved in fatty acid metabolism and neuronal signaling.
conclusionMarkers of inflammation were associated with DNA methylation signatures in YPHIV during childhood/adolescence. These epigenetic signatures may provide insight into the inflammatory pathways that contribute to chronic comorbidity risk in YPHIV and suggest inflammation as a potential target for early intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.